Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report
Autore:
Coudert, B; Anthoney, A; Fiedler, W; Droz, JP; Dieras, V; Borner, M; Smyth, JF; Morant, R; de Vries, MJ; Roelvink, M; Fumoleau, P;
Indirizzi:
Ctr GF Leclerc, F-21079 Dijon, France Ctr GF Leclerc Dijon France F-21079 tr GF Leclerc, F-21079 Dijon, France Univ Glasgow, Glasgow G61 1BDT, Lanark, Scotland Univ Glasgow Glasgow Lanark Scotland G61 1BDT G61 1BDT, Lanark, Scotland Univ Hamburg, Krankenhaus Eppendorf, D-20246 Hamburg, Germany Univ Hamburg Hamburg Germany D-20246 Eppendorf, D-20246 Hamburg, Germany Ctr Leon Berard, F-69000 Lyon, France Ctr Leon Berard Lyon France F-69000 tr Leon Berard, F-69000 Lyon, France Inst Curie, F-75005 Paris, France Inst Curie Paris France F-75005Inst Curie, F-75005 Paris, France Inst Med Oncol, Bern, Switzerland Inst Med Oncol Bern SwitzerlandInst Med Oncol, Bern, Switzerland Univ Edinburgh, Edinburgh EH4 2XU, Midlothian, Scotland Univ Edinburgh Edinburgh Midlothian Scotland EH4 2XU Midlothian, Scotland Klin Innere Med C, CH-9007 St Gallen, Switzerland Klin Innere Med C St Gallen Switzerland CH-9007 7 St Gallen, Switzerland NDDO Oncol, NL-1007 MB Amsterdam, Netherlands NDDO Oncol Amsterdam Netherlands NL-1007 MB 07 MB Amsterdam, Netherlands Ctr Rene Gauducheau, F-44000 Nantes, France Ctr Rene Gauducheau Nantes France F-44000 ucheau, F-44000 Nantes, France
Titolo Testata:
EUROPEAN JOURNAL OF CANCER
fascicolo: 17, volume: 37, anno: 2001,
pagine: 2194 - 2198
SICI:
0959-8049(200111)37:17<2194:PITWI5>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
C-RAF KINASE; ISIS-5132 CGP 69846A; ACTIVATION;
Keywords:
ISIS 5132; raf kinase; antisense; non-small cell lung cancer; small-cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Coudert, B Ctr GF Leclerc, BP 77980, F-21079 Dijon, France Ctr GF Leclerc BP 77980 Dijon France F-21079 079 Dijon, France
Citazione:
B. Coudert et al., "Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report", EUR J CANC, 37(17), 2001, pp. 2194-2198

Abstract

Two multicentre phase II trials were designed to determine if tumour responses can be achieved in progressive small-cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) patients treated with ISIS 5132, an inhibitor of C-nif kinase mRNA expression (CGP 69846A; ISIS Pharmaceuticals Inc, Carlsbad, CA), and to further characterise the safety of the compound. Between August 1998 and November 1999, 26 patients (18 NSCLC, 8 SCLC) were entered. Out of these, 23 were eligible, 22 (18 NSCLC, 4 SCLC) were treated with ISIS 5132 (2 mg/kg/day, 21 days continuous intravenous (i.v.) infusion every 4 weeks) and were evaluable for toxicity and 18 (15 NSCLC, 3 SCLC) were evaluable for efficacy. For the whole group haematological toxicity did not exceed grade 2. One patient experienced a grade 4 increased prothrombin time. Non-haematological toxicity was mild to moderate, with the observation of asthenia. and nausea and vomiting. Progressive disease (PD) was diagnosed in 10 patients (8 NSCLC and 2 SCLC). 8 more patients (7 NSCLC, 1 SCLC) were considered as treatment failures. In conclusion, this study using ISIS 5132with this dose and schedule of administration excludes a 20% response ratewith 95% confidence intervals for NSCLC and cannot draw any conclusions for SCLC patients as only a few were involved in the study. (C) 2001 ElsevierScience Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 06:49:18